The Central Drug Standard Control Organization's Subject Expert Committee has approved Novartis's protocol amendment for the TIN816 study, aimed at investigating the safety and efficacy of TIN816 in treating sepsis-associated acute kidney injury.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.